Sunny Pharmtech Inc. (6676.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan · ISIN TW0006676000

Price
9.29 TWD
Market cap
1.58 bn TWD
P/E (2024)
–
P/S (2024)
3.77
Dividend yield
0.00 %
Net margin
-37.32 %
Return on equity (ROE)
-14.90 %
Return on assets (ROA)
-9.83 %

Sunny Pharmtech Inc. financials

Fiscal year20232024
Revenue428.83 m TWD418.01 m TWD
Gross profit285.53 m TWD226.40 m TWD
Operating income-72.10 m TWD-162.99 m TWD
EBIT-52.08 m TWD-146.93 m TWD
Net income-63.32 m TWD-156.00 m TWD
Diluted EPS – continuing operations-0.44 TWD-1.05 TWD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Sunny Pharmtech Inc.

Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug formulations and raw materials in Taiwan, the United States, and internationally. It offers lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrofurantoin capsules for urinary tract infection; and aminocaproic acid tablets for blood diseases and hyper-proteolytic enzymes. It also provides carboprost tromethamine injection for therapeutic abortion and postpartum hemorrhage, as well as Cyclophosphamide injection for malignant diseases. The company was founded in 2014 and is based in Taoyuan City, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.